Journey Medical Corp reported the three months ended March 31, 2026 results: revenue $16.0 million, net income $(2.2) million, or $(0.08) per share basic and diluted, EPS $(0.08) per share basic and diluted.
“Reports First Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold”
Earnings Releases
Journey Medical Corp reported the full year ended December 31, 2025 results: revenue $61.9 million, net income Net loss was $11.4 million, or $(0.47) per share basic and diluted, EPS $(0.47) per share basic and diluted.
“2 tm269707d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi TM generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately”
Debt Financings
Journey Medical Corp amended term loan of $25.0 million with SWK Funding LLC maturing June 27, 2028.
“October 21, 2024 and the Third Amendment, the “Amended Credit Agreement”). The Amended Credit Agreement provides for a term loan facility in the original principal amount of $25.0 million. As of the date of this report, the Company has drawn the full $25.0 million, which is treated under the Amended Credit Agreement as a single loan (the “Term Loan”). The Third”
Governance Changes
Journey Medical Corp: Fourth Amended and Restated Certificate of Incorporation filed to provide for officer exculpation (effective 2025-06-24).
“effective upon filing, to provide for, among other things, officer exculpation”
Ramsey Alloush was appointed as Chief Operating Officer at Journey Medical Corp.
“On April 1, 2025, Ramsey Alloush, the General Counsel of Journey Medical Corporation (the “ Company ”), was appointed as the Company’s Chief Operating Officer.”
Michael C. Pearce was appointed as Director at Journey Medical Corp.
“appointed Michael C. Pearce, age 62, to serve on the Board”
Earnings Releases
Journey Medical Corp reported first quarter ended March 31, 2024 results: revenue Total net product revenues were $13.0 million, net income Net loss was $10.4 million, EPS $(0.53) per share basic and diluted.
“New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a”
Joseph Benesch was appointed as Chief Financial Officer at Journey Medical Corp.
“On April 26, 2024, the Board of Directors (the “ Board ”) of Journey Medical Corporation (the “ Company ”) appointed Joseph Benesch, age 57, as the Company’s permanent Chief Financial Officer.”
Earnings Releases
Journey Medical Corp reported the full year ended December 31, 2023 results: revenue $79.2 million, net income $(3.9) million, EPS $(0.21) per share basic and diluted.
“EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial”
Material Agreements
Journey Medical Corp entered into Credit Agreement with SWK Funding LLC valued at up to $20 million (effective 2023-12-27).
“On December 27, 2023 (the “ Closing Date ”), Journey Medical Corporation (the “ Company ”) entered into a Credit Agreement (the “ Credit Agreement ”), by and among the Company and SWK Funding LLC and the other the financial institutions party thereto from time to time, as lenders. The Credit Agreement provides for a term loan facility (the “ Credit Facility ”) in the original principal amount of up to $20 million.”
Dr. Jeffrey Paley resigned as Director at Journey Medical Corp.
“On December 7, 2023, Dr. Jeffrey Paley submitted his resignation from his position as a member of the Board of Directors (the “Board”) of Journey Medical Corporation (the “Company”), effective immediately.”
Earnings Releases
Journey Medical Corp reported third quarter ended September 30, 2023 results: revenue $34.5 million, net income $16.8 million, or $0.91 per share basic and $0.80 per share diluted, EPS $0.91 per share basic and $0.80 per share diluted.
“Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023 GAAP net income increased to $16.8 million, or $0.91 per share basic and $0.80 per share diluted, for the third quarter of 2023”
Listing & Compliance Notices
Journey Medical Corp received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“August 15, 2023, Journey Medical Corporation (the “ Company ” or “ Journey ”) received a deficiency letter (the “ Nasdaq Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital Market (the “ Stockholders’ Equity Requirement ”), nor is it in compliance with either of the alternative listing standards, market value of listed securities of”
Earnings Releases
Journey Medical Corp reported the second quarter ended June 30, 2023 results: revenue $17.2 million, net income GAAP net loss was $8.4 million, or $0.46 per share basic and diluted, EPS $0.46 per share basic and diluted.
“EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023 Announced positive topline results from two Phase 3 clinical trials evaluating”
Shareholder Votes
Journey Medical Corp shareholders approved Approval of the Journey Medical Corporation 2023 Employee Stock Purchase Plan at the 2023-06-21 meeting.
“Proposal 3 The vote with respect to the approval of the Journey Medical Corporation 2023 Employee Stock Purchase Plan was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 16,085,316 126,286 500 3,245,467”
Shareholder Votes
Journey Medical Corp shareholders approved Ratification of the appointment of KPMG LLP as Journey's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-21 meeting.
“Proposal 2 The vote with respect to the ratification of KPMG LLP as Journey’s independent registered accounting firm for the year ending December 31, 2023 was as follows: Total Votes For Total Votes Against Abstentions 19,431,599 25,051 919”
Shareholder Votes
Journey Medical Corp shareholders approved Election of six directors to hold office until the 2024 annual meeting of stockholders at the 2023-06-21 meeting.
“Proposal 1 The votes with respect to the election of six directors to hold office until the 2023 annual meeting of stockholders were as follows: Director Votes For Votes Withheld Broker Non-Votes Lindsay A. Rosenwald, M.D. 16,021,582 190,520 3,245,467 Claude Maraoui 16,158,703 53,399 3,245,467 Neil Herskowitz 16,140,007 72,095 3,245,467 Dr. Jeffrey Paley 16,155,835 56,267 3,245,467 Justin Smith 16,125,618 86,484 3,245,467 Miranda Toledano 16,015,287 196,815 3,245,467”
Earnings Releases
Journey Medical Corp reported first quarter ended March 31, 2023 results: revenue $12.2 million, net income $10.1 million, EPS $0.57 per share basic and diluted.
“Total net product revenues were $12.2 million for the first quarter of 2023”
Debt Financings
Journey Medical Corp amended term loan of $20 million with East West Bank at interest-only payments maturing July 1, 2024.
“Company. On January 12, 2022, the EWB Facility was amended to increase the borrowing capacity of the revolving line of credit to $10.0 million and add a term loan not to exceed $20.0 million. The Company subsequently borrowed the full $20 million under the term loan. On May 16, 2023, the Company entered into the Fifth Amendment to Loan and Security Agreement with EWB”
Material Agreements
Journey Medical Corp amended Fifth Amendment to Loan and Security Agreement with East West Bank (effective 2023-05-16).
“On May 16, 2023, the Company entered into the Fifth Amendment to Loan and Security Agreement with EWB and JGP (the "2023 Amendment").”
Earnings Releases
Journey Medical Corp reported fourth quarter ended December 31, 2022 results: revenue total revenues of $16.0 million for the fourth quarter of 2022, net income Net loss was $10.6 million, or $0.60 per share basic and diluted, for the fourth quarter of 2022, EPS $0.60 per share basic and diluted.
“This includes total revenues of $16.0 million for the fourth quarter of 2022, compared to net revenues of $17.5 million generated in the fourth quarter of 2021, representing a 9% decline from period-to-period primarily due to generic competition for Targadox.”
Earnings Releases
Journey Medical Corp reported fourth quarter and full year ended December 31, 2022 results: revenue Total revenues were $73.7 million for the full year 2022, net income Net loss was $29.6 million, or $1.69 per share basic and diluted, for the full year 2022, EPS $1.69 per share basic and diluted.
“Total revenues were $73.7 million for the full year 2022, a record high for the Company, compared to total revenues of $63.1 million for the full year 2021, representing 17% growth.”
Joseph Benesch was appointed as interim Chief Financial Officer at Journey Medical Corp.
“Joseph Benesch, age 56, the Company’s Corporate Controller, was appointed as the Company’s interim Chief Financial Officer, effective January 27, 2023.”
Ernest De Paolantonio resigned as Chief Financial Officer at Journey Medical Corp.
“On January 16, 2023, Ernest De Paolantonio, the Chief Financial Officer of Journey Medical Corporation (the “ Company ”) provided notice to the Company of his resignation, effective January 27, 2023.”
Material Agreements
Journey Medical Corp entered into At Market Issuance Sales Agreement with B. Riley Securities, Inc. valued at Agreement for the issuance and sale of up to 4,900,000 shares of common stock through agent at marke (effective 2022-12-30).
“On December 30, 2022, Journey Medical Corporation (the “Company”) entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (the “Agent”), under which the Company may offer and sell, from time to time at its sole discretion, 4,900,000 shares of its common stock, par value $0.0001 per share (the “Shares”), through or to the Agent.”
Earnings Releases
Journey Medical Corp reported the third quarter and nine months ended September 30, 2022 results: revenue $16.1 million, net income ($10.1) million, EPS ($0.57) per share basic and diluted.
“position Journey Medical for sales growth in the coming years. Journey Medical also expects to launch another product in the upcoming months.” Financial Results: · Revenues were $16.1 million for the third quarter of 2022, compared to revenues of $19.6 million for the third quarter of 2021, representing a decline of $3.5 million. The decline in revenue was”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.